Mendelian randomization analysis unveils causal associations between immune cells, metabolites, and lung cancer risk
Authors:
Open Access
- 17 November 2025
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1)
Abstract
Background Lung cancer is the leading cause of cancer-related deaths worldwide, with the highest incidence rates in the United States, posing significant public health challenges. Although treatment modalities have advanced to include chemotherapy, radiotherapy, targeted therapies, and immunotherapy, preventive strategies remain underdeveloped. Urgent research into preventive interventions is necessary due to the escalating prevalence of lung cancer, aiming to reduce both mortality rates and healthcare burden. Methods This study employed a Mendelian randomization approach using GWAS summary statistics of immunological features from the GWAS Catalogue to assess the potential causal relationship between T cell lymphocytes, celecoxib, and lung cancer risk. The analysis included various methods such as MR Egger, weighted median, inverse variance weighted, and simple mode to evaluate the robustness of these relationships. Results The analysis revealed a significant association between T cell lymphocytes and lung cancer risk, particularly when using inverse variance weighted and simple mode methods (P-values of 0.002 and 0.000, respectively). The association between celecoxib and lung cancer risk also showed significance in weighted median and inverse variance weighted approaches (P-values of 0.014 and 0.001, respectively). Additionally, specific metabolites such as phosphatidylcholine and sphingolipids were significantly associated with lung cancer risk, potentially offering new biomarkers and targets for the prevention and treatment of lung cancer. Conclusion This study, through Mendelian randomization analysis, unveiled causal relationships between T cell lymphocytes, celecoxib, and specific metabolites with lung cancer risk, providing new potential targets for the prevention and treatment of lung cancer that warrant further investigation.Keywords
This publication has 23 references indexed in Scilit:
- Characterization of human non-small cell lung cancer histology samples by atomic force microscopyNanomedicine: Nanotechnology, Biology and Medicine, 2025
- Subclonal immune evasion in non-small cell lung cancerCancer Cell, 2025
- Tumor-associated neutrophils and neutrophil extracellular traps in lung cancer: antitumor/protumor insights and therapeutic implicationsMedical Oncology, 2025
- Cellular plasticity and non-small cell lung cancer: role of T and NK cell immune evasion and acquisition of resistance to immunotherapiesCancer and Metastasis Reviews, 2025
- A combination treatment with a water extract from Euglena gracilis and anti-PD-1 antibody strongly inhibits growth of lung cancer in mice through stimulating tumor-infiltrating lymphocytesInternational Immunopharmacology, 2025
- Functional and phenotypic changes in natural killer cells expressing immune checkpoint receptors PD-1, CTLA-4, LAG-3, and TIGIT in non-small cell lung cancer: the comparative analysis of tumor microenvironment, peripheral venous blood, and tumor-draining veinsImmunologic Research, 2024
- Developing a Rhodium(III) Complex to Reprogram the Tumor Immune and Metabolic Microenvironments: Overcoming Multidrug Resistance and Metastasis in Non-Small Cell Lung CancerJournal of Medicinal Chemistry, 2024
- SiO2 stimulates macrophage stress to induce the transformation of lung fibroblasts into myofibroblasts and its relationship with the sphingomyelin metabolic pathwayJournal of Applied Toxicology, 2021
- Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibilityClinical and Translational Oncology, 2013
- Regulation of lung surfactant phospholipid synthesis and metabolismBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2013